Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncolytics Announces Additional Positive REOLYSIN® Clinical Trial Data from Phase 2 Study

Published: Monday, February 11, 2013
Last Updated: Sunday, February 10, 2013
Bookmark and Share
Study enroll patients with metastatic or recurrent squamous cell carcinoma of the lung.

Oncolytics Biotech Inc. has announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021).

The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles.

Of 20 evaluable patients, 19 (95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% shrinkage).

A waterfall graph showing individual patient data will be available on the Company's website at http://www.oncolyticsbiotech.com/presentations.

"It's exciting to have 95% of patients in this study exhibit tumour shrinkage and these results further suggest that REOLYSIN may have potential use in neoadjuvant (pre-surgical) settings," said Dr. Brad Thompson , President and CEO of Oncolytics.

Dr. Thompson continued, "Based on these findings we intend to continue to look at REOLYSIN as a treatment for cancers of the lung and cancers that metastasize to the lung."

The study enrolled patients with metastatic or recurrent squamous cell carcinoma of the lung.

The primary endpoint of the study is objective tumour response rates, and the secondary objectives include progression free survival and overall survival.

To date, the Company has observed nine partial responses (PR), nine stable disease (SD) and three progressive disease (PD) by RECIST criteria for a disease control rate (complete response (CR) + PR + SD)) of 86%. The study continues to enroll patients.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncolytics Collaborators Present Preclinical Research on Liver Cancer
Dr. Adel Jebar has presented a poster at the 8th Annual International Conference on Oncolytic Virus in UK.
Tuesday, April 15, 2014
Oncolytics Collaborators Present at UK Oncolytic Virus Conference
Collaborators present translational brain cancer clinical data and immunomodulatory preclinical research.
Tuesday, April 15, 2014
Oncolytics Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma
Research collaborators will make two poster presentations at the AACR 2014 Annual Meeting.
Tuesday, April 08, 2014
Oncolytics Biotech® Announces Third Quarter 2013 Results
Company announces its financial results and operational highlights.
Monday, November 11, 2013
Oncolytics Biotech® Announces Addition to Senior Management Team
Appointment of Dr. Jeremy Grushcow to the role of General Counsel.
Monday, September 16, 2013
Oncolytics Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN®
Final progression-free survival and safety data for the study will be reported later in 2013.
Tuesday, September 10, 2013
Oncolytics Meets Primary Endpoint in U.S. Phase 2 Study of REOLYSIN®
Company has met primary overall statistical endpoint in U.S. Phase 2 clinical trial in SCCLC patients.
Tuesday, May 28, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
Company announces preliminary results from trial in patients using intravenous administration of REOLYSIN®.
Monday, May 27, 2013
Oncolytics Announces 2012 Year End Results
Company has completed two financings over the last 14 months raising gross proceeds in excess of $50 million.
Tuesday, March 19, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase II Clinical Trial
Investigating REOLYSIN® in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.
Thursday, February 21, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 SCLC Clinical Trial
Primary objective of the trial is to assess the antitumor effect of the treatment regimen.
Friday, February 01, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase I Clinical Trial
Phase I clinical trial investigate REOLYSIN® in combination with FOLFIRI in patients with colorectal cancer.
Monday, August 27, 2012
Oncolytics Completes Patient Enrollment in U.K. Phase I Clinical Trial
Phase I clinical trial investigate REOLYSIN® in combination with cyclophosphamide in patients with advanced malignances.
Monday, August 27, 2012
Oncolytics Announces Second Quarter 2012 Results
Company announces completion of enrollment in the first, 80-patient stage of Phase III clinical trial in head and neck cancers.
Monday, August 06, 2012
Oncolytics Enters into Sponsorship Agreement with NCIC CTG
Agreement for randomized phase II study in advanced and metastatic breast cancers.
Friday, June 22, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!